---
title: Improve walking speed through exercise
nct_id: NCT07057219
phase: NA
status: RECRUITING
sponsor: The University of New South Wales
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07057219"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07057219"
last_fetched: "2026-05-10T14:08:27.716Z"
source: "Parkinson's Pathways (curated)"
---
# Improve walking speed through exercise

**Goal (in five words):** Improve walking speed through exercise

**Official Title:** StepuP: Steps Against the Burden of Parkinson's Disease

**Trial ID:** [NCT07057219](https://clinicaltrials.gov/study/NCT07057219)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** The University of New South Wales
- **Target Enrollment:** 42 participants
- **Start Date:** 2025-07-09
- **Completion Date:** 2026-09-30
- **Conditions:** Parkinson Disease (PD)
- **Interventions:** Exercise, Exercise
- **Intervention Types:** OTHER

## Summary For Families

The trial aims to ease the walking and mobility problems many people with Parkinson's face, specifically targeting those with mild to moderate gait impairment. It tests a structured exercise program designed to build leg strength, balance, endurance and motor control, which can improve walking patterns and may promote neuroplasticity; the exercises are meant to complement, not replace, medications such as levodopa. Adults 18 and older with Parkinson's in Hoehn and Yahr stages I to III who have at least a mild gait score on the MDS-UPDRS, can walk at least one floor, and can give informed consent are eligible, while people with major medical risks for unsupervised exercise, severe depression or cognitive impairment, implanted DBS, or other significant exclusions are not.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Diagnosis of PD according to the MDS Criteria
2. Hoehn and Yahr stages I to III;
3. Movement Disorder Society-sponsored version of the Unified Parkinson Disease Rating Scale (MDS-UPDRS) gait sub-score of 1 or more
4. Signed informed consent to participation

Exclusion Criteria:

* Any known general health condition likely to interfere with or to pose a contraindication to non-medically supervised physical exercise.
* Moderate or severe depression (BDI-II ≥18)
* Cognitive impairment which may preclude the possibility to provide a fully informed consent to enrolment.
* Linguistic comprehension capacity less than 75% in ordinary conversation
* Severe psychiatric comorbidity which may interfere with compliance to the study protocol
* History of or current status of substance dependency
* Unable to walk less than 1 floor
* Thoracic pain in the last 4 weeks
* Currently enrolled in other interventional studies
* Implanted Deep Brain Stimulation device
```

## Locations (1)

- Neuroscience Research Australia, Randwick, New South Wales, Australia _(-33.9144, 151.2490)_
  - Matthew A Brodie, PhD — (CONTACT) — +61 449 886 272 — a.m.brodie@unsw.edu.au
  - Yoshiro Okubo, PhD — (CONTACT) — +61 293991065 — y.okubo@neura.edu.au

## Central Contacts

- Matthew A Brodie, PhD — (CONTACT) — +614 4988 6272 — a.m.brodie@unsw.edu.au
- Yoshiro Okubo, PhD — (CONTACT) — +61 293991065 — y.okubo@neura.edu.au

---

*Canonical: https://parkinsonspathways.com/trial/NCT07057219*  
*HTML version: https://parkinsonspathways.com/trial/NCT07057219*  
*Source data: https://clinicaltrials.gov/study/NCT07057219*